Volume 10, Issue 1 (Winter 2021)                   J Occup Health Epidemiol 2021, 10(1): 12-16 | Back to browse issues page

‎ 10.52547/johe.10.1.12
‎ 20.1001.1.22518096.2021.10.1.3.2

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kafi M, Karimifard M, Amiorroaya S. Diabetic Ketoacidosis and COVID-19: Two Case Reports. J Occup Health Epidemiol 2021; 10 (1) :12-16
URL: http://johe.rums.ac.ir/article-1-415-en.html
Related article in
Google Scholar
Similar articles
Survey of stressful life events among diabetic and non-diabetic elderly individuals in Rafsanjan, Iran, in 2015
Associations between Wearing Masks, Hand Washing, and the Risk of COVID-19 Contraction: A Case-Control Study in the Northwest of Iran
The Effect of Working-based Individual Protective Behaviors (WIPB) on COVID-19 Mortality in North-West of Iran: A Case-Control Study
The Role of Aerobic Exercise in the Gene Expression of Metallo Proteinase-2 and Angiostatin in Diabetic Rats' Heart Tissue
The prevalence of depression and related factors in diabetic patients referred to Rafsanjan diabetes center, Iran, 2016
Case Report
Diabetic Ketoacidosis and COVID-19: Two Case Reports
Mehdi Kafi1 , Maryam Karimifard * 2, Sima Amiorroaya3
1- Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
2- Assistant Prof., Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. , karimifardmaryam6@gmail.com
3- Associate Prof., Dept. of Engineering and Mathematics, Sheffield Hallam University, Sheffield S1 1WB, UK.
Article history
Received: 2020/12/14
Accepted: 2021/03/2
ePublished: 2021/03/29
Subject: Epidemiology
Abstract:   (1698 Views)

Background: COVID-19 is a viral infection that causes pneumonia with dyspnea, cough, and fever. Its outcomes are more severe in patients with diabetes, hypertension, and other disorders than in healthy people. New-onset diabetes and diabetic ketoacidosis (DKA) have been reported as the complications of COVID-19 in several studies. It seems that the prevalence of DKA due to Covid-19 is increasing. Therefore, two cases of individuals with DKA due to COVID-19 are presented in this study to inform other researchers about the details of this phenomenon.
Material and Methods: Demographic characteristics, medical histories, physical examinations, laboratory investigations, real-time RT-PCR tests, computed tomography (CT) imaging studies, given treatments, clinical courses, and management outcomes were documented prospectively.
Results: In the present experience, the manifestation of COVID-19 disease in the second case with a history of diabetes was more severe than in the first case. In the second case, with underlying diabetes and COVID-19, the DKA manifestation was associated with consciousness loss, severe restlessness, and respiratory distress; however, in the first case, with COVID-19 without diabetes, the DKA manifestation was associated with anorexia, weight loss, and lack of respiratory distress, which were milder symptoms than the second case.
Conclusion: Due to the high prevalence of diabetes mellitus and COVID-19 in Iran, it is recommended to raise awareness of DKA symptoms among health professionals.

Keywords: Diabetes Complications [MeSH], Diabetic Ketoacidosis [MeSH], Covid-19 [MeSH]
Full-Text [PDF 473 kb]   (860 Downloads) |   |   Full-Text (HTML)  (461 Views)  
References
1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA 2020; 323(8):709-10. [DOI] [PMID]
2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323(11):1061-9. [DOI] [PMID] [PMCID]
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu, Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223):497–506. [DOI] [PMID] [PMCID]
4. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. J Infection 2020; 80(4):388-93. [DOI] [PMID] [PMCID]
5. Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A. Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality - United States, 2000–2014. MMWR Morb Mortal Wkly Rep 2018; 67(12):362-5. [DOI] [PMID] [PMCID]
6. Gautam S. The Influence of COVID-19 on Air Quality in India: A Boon or Inutile. Bull Environ Contam Toxicol 2020; 104:724-6. [DOI]
7. Plewa MC, Bryant M, King-Thiele R. Euglycemic Diabetic Ketoacidosis. Treasure Island (FL), Florida, United States: StatPearls Publishing; 2021. [PMID]
8. Reddy PK, Kuchay MS, Mehta Y, Mishra SK. Diabetic ketoacidosis precipitated by COVID-19: A report of two cases and review of literature. Diabetes Metab Syndr 2020; 14(5):1459-62. [DOI] [PMID] [PMCID]
9. Palermo NE, Sadhu AR, McDonnell ME. Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations. J Clin Endocrinol Metab 2020; 105(8):dgaa360. [DOI] [PMID] [PMCID]
10. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 2020; 8(9):782-92. [DOI] [PMID] [PMCID]
11. Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID‐19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 2020; 22(10):1935-41. [DOI] [PMID] [PMCID]
12. Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin‐converting enzyme‐2 (ACE2), SARS‐CoV‐2 and pathophysiology of coronavirus disease 2019 (COVID‐19). J Pathol 2020; 251(3):228-48. [DOI] [PMID] [PMCID]
13. Rodríguez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve DM, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun 2020; 114:102506. [DOI] [PMID] [PMCID]
14. Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol 2020; 2(10):e594-602. [DOI] [PMID] [PMCID]
15. Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, et al. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 2012; 97(9):3333-41. [DOI] [PMID] [PMCID]
16. Pinheiro MM, Stoppa CL, Valduga CJ, Okuyama CE, Gorjão R, Pereira RM, et al. Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro. Eur J Pharm Sci 2017; 100:17-24. [DOI] [PMID]
17. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43(Suppl 1):S14-31. [DOI] [PMID]
18. Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism 2016; 65(4):507-21. [DOI] [PMID]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

2024 CC BY 4.0 | Journal of Occupational Health and Epidemiology

Designed & Developed by : Yektaweb